Roberto Salgado

10.3k citations

37 papers · 822 indexed · 1 hit paper · h-index 12

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- CAR-T cell therapy research
Cancer Research top 10%
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies

Papers in

Cancer Research 17
- Cancer Genomics and Diagnostics 11
- Breast Cancer Treatment Studies 8
Health Informatics 1

Co-authors: Christos Sotiriou Sherene Loi Sanne Lysbet de Haas Michelino De Laurentiis Francisco J. Esteva Jigna Shah Mark Beresford Haiying Liu
Journals: Cancer Research (7 papers)Journal of Clinical Oncology (5 papers)Clinical Chemistry and Laboratory Medicine (CCLM) (2 papers)European Journal of Cancer (2 papers)Molecular Cancer Therapeutics (1 paper)
Partner nations: Belgium United States Australia

In The Last Decade

Roberto Salgado

30 papers receiving 815 citations

Hit Papers

align trajectories log scale

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial 2020 · 280 citations

Peers

Countries citing papers authored by Roberto Salgado

Since Specialization

Citations

This map shows the geographic impact of Roberto Salgado's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Salgado with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Salgado more than expected).

Fields of papers citing papers by Roberto Salgado

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Salgado. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Salgado. The network helps show where Roberto Salgado may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Roberto Salgado, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Roberto Salgado Line = papers co-authored together Roberto Salgado links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Regulation of laboratory-developed tests and in-house in vitro diagnostic medical devices in the United States and the European Union—a comparative overview ESMO Open ·André Kahles, Алиев Тахир Аскерович, 刘新圣, Manuel Salto‐Tellez, Michael Vogeser, Jack Stone, Monika Brüggemann, Jan Budczies, Daniel Kazdal, Roberto Salgado, Peter Schirmacher, Susan E. Peters, Jochen K. Lennerz, Albrecht Stenzinger	2025	0
2	AI assessment of tumor-infiltrating lymphocytes on routine H&E-slides as a predictor of response to neoadjuvant therapy in breast cancer—a real-world study Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Vince Leslie, 俊龚, Anne Marie Bak Jylling, Roberto Salgado, TAKEOMI AKIMARU, Mattias Rantalainen, Anne‐Vibeke Lænkholm	2025	0
3	Analysis of the Radiosensitivity Index in Paired Preneoadjuvant and Postneoadjuvant Therapy Triple-Negative Breast Cancer International Journal of Radiation OncologyBiologyPhysics ·Shane R. Stecklein, Roberto Salgado, Julia White, Bruce F. Kimler, Rachel Yoder, Joshua M. Staley, Anne O’Dea, Lauren Nye, 许书鹏 Xu Shupeng, Gregory Crane, Rashna Madan, Maura O’Neil, Andrew K. Godwin, Harsh B. Pathak, Qamar J. Khan, Joyce O’Shaughnessy, Priyanka Sharma	2025	0
4	Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant IO trials (PATHdata): Final analysis of a multi-institutional reproducibility study. Journal of Clinical Oncology ·Julie S. Deutsch, Tricia R. Cottrell, Krista Y. Chen, Carlos E. de Andrea, Ezra Baraban, Pierre Fiset, Jaroslaw Jedrych, 洋明石上, Roberto Salgado, Christian M. Schürch, Richard A. Scolyer, Raja R. Seethala, Lynette M. Sholl, Sabina Signoretti, Michael T. Tetzlaff, Annikka Weissferdt, Xiaowei Xu, James Ziai, Ashley Cimino‐Mathews, Janis M. Taube	2024	0
5	Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis European Journal of Cancer ·Diogo Martins-Branco, Guilherme Nader Marta, Chiara Molinelli, Lieveke Ameye, Marianne Paesmans, Michail Ignatiadis, Philippe Aftimos, Roberto Salgado, Evandro de Azambuja	2023	7
6	Abstract PD11-07: PD11-07 Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a correlative analysis from NeoPACT and NeoSTOP trials Cancer Research ·Priyanka Sharma, Shane R. Stecklein, Rachel Yoder, Joshua M. Staley, Roberto Salgado, Laia Paré, Benedetta Conte, Fara Brasó‐Maristany, Anne O’Dea, Lauren Nye, Manana Elia, 许书鹏 Xu Shupeng, Gregory Crane, 胡安全, Qamar J. Khan, Andrew K. Godwin, Aleix Prat	2023	2
7	Selecting patients with HER2-low breast cancer: Getting out of the tangle European Journal of Cancer ·Darko Pavlovic, Roberto Salgado, Carsten Denkert, Jochen K. Lennerz, Frédérique Penault‐Llorca, Giuseppe Viale, John M.S. Bartlett, Carolien H. M. van Deurzen	2022	31
8	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial The Lancet Oncology ·Leisha A. Emens, Francisco J. Esteva, Mark Beresford, Cristina Saura, Michelino De Laurentiis, Sung‐Bae Kim, Seock‐Ah Im, Yifan Wang, Roberto Salgado, Aruna Mani, Jigna Shah, Chiara Lambertini, Haiying Liu, Sanne Lysbet de Haas, Monika Patre, Sherene Loi Hit paper breakdown →	2020	280
9	Tumor Banks: A Quality Control Scheme Proposal Frontiers in Medicine ·Ligia Craciun, Gigih Tri Wicaksono, RenDong-mei, Roberto Salgado, Alexandre de Wind, Pieter Demetter, Laurine Verset, О А Угланова, L. Liu, Nicolas Sirtaine, С. Б. Дохолян, Ioanna Laı̈os, A. Warnsing, Denis Larsimont	2019	8
10	DNA methylation–based immune response signature improves patient diagnosis in multiple cancers Journal of Clinical Investigation ·Jana Jeschke, Martin Bizet, Christine Desmedt, Emilie Calonne, Sarah Dedeurwaerder, Soizic Garaud, Alexander Koch, Denis Larsimont, Roberto Salgado, Gert Van den Eynden, 潤一高見澤, Gianluca Bontempi, Matthieu Defrance, Christos Sotiriou, François Fuks	2017	110
11	Network science in clinical trials: A patient-centered approach Seminars in Cancer Biology ·Venkata Manem, Roberto Salgado, Philippe Aftimos, Christos Sotiriou, Benjamin Haibe‐Kains	2017	10
12	Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker? Current Breast Cancer Reports ·Sathana Dushyanthen, Peter Savas, Karen Willard‐Gallo, Carsten Denkert, Roberto Salgado, Sherene Loi	2015	3
13	Liquid biopsy Current Opinion in Oncology ·Isabelle Gingras, Roberto Salgado, Michail Ignatiadis	2015	30
14	Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data Genome biology ·Ingrid Lönnstedt, Franco Caramia, Jason Li, Debora Fumagalli, Roberto Salgado, Andrew Rowan, Max Salm, Nnennaya Kanu, Peter Savas, Stuart Horswell, Stephan Gade, Sibylle Loibl, Patrick Neven, Christos Sotiriou, Charles Swanton, Sherene Loi, Terence P. Speed	2014	11
15	Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology BMC Genomics ·Debora Fumagalli, Alexis Blanchet-Cohen, David N. Brown, Christine Desmedt, David Gacquer, Stefan Michiels, Françoise Rothé, Samira Majjaj, Roberto Salgado, Denis Larsimont, Michail Ignatiadis, Marion Maetens, Martine Piccart, Vincent Detours, Christos Sotiriou, Benjamin Haibe‐Kains	2014	42
16	Abstract P1-07-08: Effect of sample preservation method and transportation duration on tumor gene expression profiling in breast cancer. Cancer Research ·Debora Fumagalli, Vinu José, Roberto Salgado, Samira Majjaj, Sandeep K. Singhal, Delphine Vincent, Marion Maetens, Denis Larsimont, 张燕翎, Phuong Dinh, M. Piccart, Stefan Michiels, Christos Sotiriou, Sherene Loi	2012	1
17	Metasin-BLNA: The NHS Solution Cost Effective-Rapid Intraoperative Molecular Assessment of Sentinel Lymph Nodes from Breast Cancer Patients European Journal of Surgical Oncology ·Vasi Sundaresan, Juliet Paola Rincón Noriega, Helva Guslaw, Shirly Bar-Amotz, R.E. Mansel, Ian A. Cree, Denis Larsimont, Roberto Salgado	2011	1
18	Use of meta-analysis of gene expression profiling studies to identify biologically relevant pathways associated with aggressive breast cancer (BC) in young women. Journal of Clinical Oncology ·Philippe L. Bédard, Roberto Salgado, Esther A. Koop, Virginie Durbecq, Michail Ignatiadis, Benjamin Haibe‐Kains, M. Piccart, Christos Sotiriou, Sherene Loi	2010	1
19	Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer Molecular Cancer Therapeutics ·Lissandra Dal Lago, Virginie Durbecq, Christine Desmedt, Roberto Salgado, Thibault Verjat, Laurence Lespagnard, Yan Ma, Isabelle Veys, Angelo Di Leo, Christos Sotiriou, Martine Piccart, Denis Larsimont	2006	59
20	Eosinophilic cellulitis or Wells’ syndrome in a 6-year-old child European Journal of Pediatrics ·E.R. DESOMBRE, Marek Wojciechowski, Roberto Salgado, R. G. de Moya, H M Lee, Margo M. Hagendorens	2005	7

About Roberto Salgado

Roberto Salgado is a scholar working on Cancer Research, Health Informatics, Oncology, Radiology, Nuclear Medicine and Imaging and Statistics, Probability and Uncertainty, having authored 37 papers that have together received 822 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (11 papers), Cancer Genomics and Diagnostics (11 papers), Breast Cancer Treatment Studies (8 papers), Radiomics and Machine Learning in Medical Imaging (5 papers), HER2/EGFR in Cancer Research (5 papers), Molecular Biology Techniques and Applications (4 papers), AI in cancer detection (3 papers) and Ferroptosis and cancer prognosis (3 papers). The work is most often cited by research in Oncology (555 citations), Cancer Research (246 citations), Radiology, Nuclear Medicine and Imaging (204 citations), Health Informatics (11 citations) and Immunology (133 citations). Roberto Salgado has collaborated with scholars based in Belgium, United States and Australia. Frequent co-authors include Christos Sotiriou, Sherene Loi, Sanne Lysbet de Haas, Michelino De Laurentiis, Francisco J. Esteva, Jigna Shah, Mark Beresford, Haiying Liu, Cristina Saura and Yifan Wang. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Clinical Chemistry and Laboratory Medicine (CCLM), European Journal of Cancer and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact